Outcome of Azacitidine therapy in acute myeloid leukemia is not improved by concurrent Vorinostat therapy but is predicted by a diagnostic molecular signature.
AffiliationSchool of Medicine, University of Birmingham
MetadataShow full item record
AbstractPurpose: Azacitidine (AZA) is a novel therapeutic option in older patients with acute myeloid leukemia (AML) but its rational utilization is compromised by the fact that neither the determinants of clinical response nor its mechanism of action are defined. Co-administration of histone deacetylase inhibitors, such as vorinostat (VOR), is reported to improve the clinical activity of AZA but this has not been prospectively studied in AML. Experimental Design: We compared outcomes in 259 adults with AML (n=217) and MDS (n=42) randomized to receive either AZA monotherapy (75 mg/m(2) × seven days every 28 days) or AZA combined with VOR 300 mg bd on days 3-9 po. Next generation sequencing was performed in 250 patients on 41 genes commonly mutated in AML. Serial immunophenotyping of progenitor cells was performed in 47 patients. Results: Co-administration of VOR did not increase the overall response rate (P=0.84) or overall survival (OS) (P=0.32). Specifically, no benefit was identified in either de novo or relapsed AML. Mutations in the genes CDKN2A (P=0.0001), IDH1 (P=0.004) and TP53 (P=0.003) was associated with reduced OS. Lymphoid multi-potential progenitor populations were greatly expanded at diagnosis and although reduced in size in responding patients remained detectable throughout treatment. Conclusion: This study demonstrates no benefit of concurrent administration of VOR with AZA but identifies a mutational signature predictive of outcome after AZA based therapy. The correlation between heterozygous loss of function CDKN2A mutations and decreased OS implicates induction of cell cycle arrest as a mechanism by which AZA exerts its clinical activity.
CitationOutcome of Azacitidine therapy in acute myeloid leukemia is not improved by concurrent Vorinostat therapy but is predicted by a diagnostic molecular signature.. 2017 Clin. Cancer Res.
JournalClinical Cancer Research
- A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.
- Authors: Kirschbaum M, Gojo I, Goldberg SL, Bredeson C, Kujawski LA, Yang A, Marks P, Frankel P, Sun X, Tosolini A, Eid JE, Lubiniecki GM, Issa JP
- Issue date: 2014 Oct
- Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study.
- Authors: Walter RB, Medeiros BC, Gardner KM, Orlowski KF, Gallegos L, Scott BL, Hendrie PC, Estey EH
- Issue date: 2014 Jan
- A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia.
- Authors: How J, Minden MD, Brian L, Chen EX, Brandwein J, Schuh AC, Schimmer AD, Gupta V, Webster S, Degelder T, Haines P, Stayner LA, McGill S, Wang L, Piekarz R, Wong T, Siu LL, Espinoza-Delgado I, Holleran JL, Egorin MJ, Yee KW
- Issue date: 2015
- Combination therapy with azacitidine, etoposide, and cytarabine in the treatment of elderly acute myeloid leukemia patients: A single center experience.
- Authors: Onec B, Okutan H, Albayrak M, Can ES, Aslan V, Koluman BU, Kosemehmetoglu OS, Albayrak A
- Issue date: 2018 Jul-Sep
- Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.
- Authors: Fu S, Hou MM, Naing A, Janku F, Hess K, Zinner R, Subbiah V, Hong D, Wheler J, Piha-Paul S, Tsimberidou A, Karp D, Araujo D, Kee B, Hwu P, Wolff R, Kurzrock R, Meric-Bernstam F
- Issue date: 2015 May